A new article highlights Orforglipron, Cagrilintide, and the Libre Assist as potential breakthroughs in diabetes management, though the complete details remain behind a paywall. Published by Hcplive, the piece underscores the continued push toward innovative therapies and technologies for people living with diabetes.